– Leverages Poseida’s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors – TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.